ClinicalTrials.gg
CompletedNCT00041977Updated Jun 24, 2005

Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea

A Phase 3 interventional study of doxycycline hyclate 20 mg twice daily in Acne Rosacea, sponsored by CollaGenex Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by CollaGenex Pharmaceuticals (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.

Enrollment
6th of 12
150 · median 150
Started
2002
the only one that year
Phase 3
2 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
3 of 12
CollaGenex Pharmaceuticals

Among the 12 studies testing doxycycline in Rosacea, this one is the 6th largest by enrollment, is the only one that started in 2002, is one of 2 in phase 3, and was the 1st registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing doxycycline in Rosacea as a file.
02

Study summary

The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and overall redness associated with rosacea.

03

Conditions studied

  • Acne Rosacea

Browse trials for

Keywords

  • Rosacea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, post-pubescent male and females > age 18, with rosacea, 10 to 30, [papules and pustules] and \< 2 nodules.
  • Presence of moderate to severe erythema.
  • Presence of telangiectasia.
  • Female patients must utilize one of the following methods of throughout the study: IUD, diaphragm, a condom plus the use of a spermicidal gel or foam, oral contraceptives (provided patient has been utilizing this method for at least 4 months prior to baseline and has not changed the brand within this period). Patients may also participate if they are surgically sterilized, in a monogamous relationship with a sterile partner, or sign an agreement that they will abstain from sexual intercourse during the course of a study.
  • Patients must sign an form.
  • Negative pregnancy test and non-lactating.

Exclusion criteria

Exclusion Criteria

  • The initiation of a hormonal method of within 4 months of baseline; or discontinuation during the course of study; or change in the actual product within 4 months of baseline or during the study.
  • The use of topical acne treatments within 2 weeks of baseline.
  • The use of systemic antibiotics within 4 weeks of baseline.
  • The use of an drug with 90 days of baseline.
  • Pregnant women or women of who are not using an adequate form of birth control as described in Item 4 of the Inclusion Criteria.
  • Nursing women.
  • Patients with a known to tetracyclines.
  • Patients on , concomitant drug therapy (See section below).
  • The use of any acne treatment during the course of the study.
  • The use of topical 6 weeks prior to baseline and during the study.
  • The use of systemic corticosteroids 6 weeks prior to baseline and during the study.
  • The use of vasodilators 6 weeks prior to baseline or during the study.
  • The use of α-adrenergic receptor-blocking agents 6 weeks prior to baseline and during the study.

Prohibited Medications:

  • Chronic use (> 14 days) of sulfa drugs, erythromycin, cephalosporins, and quinolones.
  • The use of tetracycline antibiotics is prohibited.
  • Use of any acne treatment during the course of the study, including spironolactone.
  • Chronic use (> 14 days) of NSAIDs. Chronic use of aspirin at sub-analgesic doses (\< 325 mg q.d.) may be used by those patient requiring aggregation inhibitor.
  • Penicillin antibiotics should NOT be used during the course of this trial since the bacteriostatic action of doxycycline may interfere with the bactericidal action of penicillins.
  • Antacids and vitamins containing aluminum, calcium, or magnesium may impair drug absorption and should be taken at least 1.5 hours before or 3.0 hours after taking study medication.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
150 participants
06

Study locations

7 sites
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Miami Medical Center
    Miami, Florida 33136, United States
  • Beer and Houck/Florida Dermatology Institute
    West Palm Beach, Florida 33104, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • David Pariser, MD
    Norfolk, Virginia 23507, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00041977
First posted
Jul 23, 2002
Start date
Jun 2002
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2003. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion